Kimryn Rathmell – NCI supported researchers have developed a new prostate cancer urinary biomarker test
Kimryn Rathmell shared on X:
“NCI-supported researchers have developed and validated a new prostate cancer urinary biomarker test that can help differentiate who should proceed for biopsy after an elevated prostate-specific antigen (PSA) test from those who can wait.”
Read further.
Source: Kimryn Rathmell/X
Dr. Kimryn Rathmell is a distinguished leader and researcher in the field of kidney cancer. Specializing in the research and treatment of complex and hereditary kidney cancers.
She has held leadership positions with organizations such as the American Society of Clinical Oncology and the American Society for Clinical Investigation, she has been elected to esteemed academies including the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.
Currently serving as the director of the National Cancer Institute, Dr. Rathmell continues to lead research initiatives and advance the understanding and treatment of kidney cancer, ultimately improving the lives of patients worldwide.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023